{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:32:24Z","timestamp":1787020344670,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The immunity of patients with lung cancer decreases after treatment; thus, they are easily infected with pathogenic bacteria that causes pulmonary infections. Understanding the distribution characteristics of pathogenic bacteria in pulmonary infection in patients with lung cancer after treatment can provide a basis to effectively prevent infection and rationally use antibacterial drugs. However, no meta-analyses have assessed the distribution characteristics of pathogenic bacteria in mainland China. Therefore, our meta-analysis aimed to investigate the pathogen distribution in pulmonary infection in Chinese patients with lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A literature search was conducted to study the pathogen distribution in pulmonary infection in Chinese patients with lung cancer between January 1, 2020 and December 31, 2022, using English and Chinese databases. The relevant data were extracted. The meta-analysis was performed using a random-effects model ( I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009&gt;\u200950%) with 95% confidence intervals for forest plots. Data were processed using RevMan 5.3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifteen studies (2,683 strains in 2,129 patients with pulmonary infection were cultured) met the evaluation criteria. The results showed that Gram-negative bacteria had the highest detection rate (63%), followed by Gram-positive bacteria (23%), and fungi (12%). Among the Gram-negative bacteria detected, the distribution of the main pathogenic bacteria was\n                      <jats:italic>Klebsiella pneumonia<\/jats:italic>\n                      (17%),\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (14%),\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      (13%),\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (7%),\n                      <jats:italic>Enterobacter cloacae<\/jats:italic>\n                      (4%), and\n                      <jats:italic>Hemophilus influenza<\/jats:italic>\n                      (4%). Moreover, the prevalence of pulmonary infections after chemotherapy (53%) was significantly higher than that after surgery (10%), P\u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of pulmonary infections after treatment, especially after chemotherapy, is high in Chinese patients with lung cancer, and Gram-negative bacteria are the predominant pathogens. Further studies are needed to monitor the prevalence of pulmonary infections and pathogen distribution in lung cancer patients in mainland China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-023-02681-4","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T09:01:53Z","timestamp":1698051713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pathogen distribution in pulmonary infection in chinese patients with lung cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Yanyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"issue":"1","key":"2681_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2681_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/atm.2016.03.11","volume":"4","author":"J Didkowska","year":"2016","unstructured":"Didkowska J, Wojciechowska U, Ma\u0144czuk M, \u0141obaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016;4(8):11.","journal-title":"Ann Transl Med"},{"issue":"3","key":"2681_CR3","doi-asserted-by":"publisher","first-page":"03","DOI":"10.21037\/cco.2019.06.03","volume":"8","author":"CC Lin","year":"2019","unstructured":"Lin CC. Challenges of the phase I drug development in non-small cell lung cancer. Chin Clin Oncol. 2019;8(3):03.","journal-title":"Chin Clin Oncol"},{"issue":"Supplementum 1","key":"2681_CR4","first-page":"35","volume":"34","author":"V Jedli\u010dka","year":"2021","unstructured":"Jedli\u010dka V. Surgical treatment of lung cancer. Klin Onkol. 2021;34(Supplementum 1):35\u201342.","journal-title":"Klin Onkol"},{"issue":"6","key":"2681_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.resinv.2014.06.003","volume":"52","author":"K Suda","year":"2014","unstructured":"Suda K, Sato K, Mizuuchi H, Kobayashi Y, Shimoji M, Tomizawa K, Takemoto T, Iwasaki T, Sakaguchi M, Mitsudomi T. Recent evidence, advances, and current practices in surgical treatment of lung cancer. Respir Investig. 2014;52(6):322\u20139.","journal-title":"Respir Investig"},{"issue":"3","key":"2681_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/ALN.0000000000003873","volume":"135","author":"ZZ Xu","year":"2021","unstructured":"Xu ZZ, Li HJ, Li MH, Huang SM, Li X, Liu QH, Li J, Li XY, Wang DX, Sessler DI. Epidural anesthesia-analgesia and recurrence-free survival after Lung Cancer surgery: a Randomized Trial. Anesthesiology. 2021;135(3):419\u201332.","journal-title":"Anesthesiology"},{"issue":"1","key":"2681_CR7","doi-asserted-by":"publisher","first-page":"019","DOI":"10.1186\/s13045-019-0736-3","volume":"12","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):019\u2013736.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2681_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell Lung Cancer. J Clin Oncol. 2022;40(6):586\u201397.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2681_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","volume":"13","author":"R Ruiz-Cordero","year":"2020","unstructured":"Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in Lung Cancer. Surg Pathol Clin. 2020;13(1):17\u201333.","journal-title":"Surg Pathol Clin"},{"issue":"5","key":"2681_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/resp.12789","volume":"21","author":"A Steven","year":"2016","unstructured":"Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21(5):821\u201333.","journal-title":"Respirology"},{"key":"2681_CR11","doi-asserted-by":"crossref","unstructured":"Zhang Q, Tang L, Zhou Y, He W, Li W. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: current understanding in characteristics, diagnosis, and management. Front Immunol 2021, 12(663986).","DOI":"10.3389\/fimmu.2021.663986"},{"key":"2681_CR12","doi-asserted-by":"crossref","unstructured":"Budisan L, Zanoaga O, Braicu C, Pirlog R, Covaliu B, Esanu V, Korban SS, Berindan-Neagoe I. Links between infections, Lung Cancer, and the Immune System. Int J Mol Sci 2021, 22(17).","DOI":"10.3390\/ijms22179394"},{"issue":"137","key":"2681_CR13","first-page":"1749","volume":"6","author":"P Apostolou","year":"2011","unstructured":"Apostolou P, Tsantsaridou A, Papasotiriou I, Toloudi M, Chatziioannou M, Giamouzis G. Bacterial and fungal microflora in surgically removed lung cancer samples. J Cardiothorac Surg. 2011;6(137):1749\u20138090.","journal-title":"J Cardiothorac Surg"},{"key":"2681_CR14","doi-asserted-by":"crossref","unstructured":"Guo W, Gao G, Dai J, Sun Q. Prediction of pulmonary infection during Palliative Chemotherapy of Lung Cancer based on Artificial neural network. Comput Math Methods Med 2022, 10(4312117).","DOI":"10.1155\/2022\/4312117"},{"issue":"120374","key":"2681_CR15","first-page":"4","volume":"294","author":"B Patel","year":"2022","unstructured":"Patel B, Priefer R. Impact of chronic obstructive pulmonary disease, pulmonary infection, and\/or inhaled corticosteroids use on potential risk of lung cancer. Life Sci. 2022;294(120374):4.","journal-title":"Life Sci"},{"issue":"39","key":"2681_CR16","first-page":"160","volume":"2","author":"AX Hu","year":"2022","unstructured":"Hu AX. Risk factors of pulmonary infection in patients with lung cancer after pulmonary resection. J Xinxiang Med Universtiy. 2022;2(39):160\u20134. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=XXYX202202012. &DbName=CJFQ2022 (in Chinese).","journal-title":"J Xinxiang Med Universtiy"},{"issue":"4","key":"2681_CR17","first-page":"247","volume":"23","author":"B Xu","year":"2021","unstructured":"Xu B, Sha JM, Zhao XD, Cao W, Zhou X, Wu JX, Xu SS. Analysis of Pathogen characteristics and Multi-drug Resistance of Nosocomial Pulmonary infection after Lung Cancer Operation. Chin J Med Guide. 2021;23(4):247\u201350. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=DKYY202104002. &DbName=CJFQ2021 (in Chinese).","journal-title":"Chin J Med Guide"},{"issue":"22","key":"2681_CR18","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.13241\/j.cnki.pmb.2022.12.011","volume":"12","author":"F Gao","year":"2022","unstructured":"Gao F, He Y, Lu ZH, Shi Y, Lin S, Zhang BX. Retrospective study on pathogenic Bacteria distribution and influencing factors of postoperative pulmonary infection in Lung Cancer. Progress in Modern Biomedicine. 2022;12(22):2255\u20139. https:\/\/doi.org\/10.13241\/j.cnki.pmb.2022.12.011. (in Chinese).","journal-title":"Progress in Modern Biomedicine"},{"issue":"2","key":"2681_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.13461\/j.cnki.wna.005446","volume":"43","author":"G Meng","year":"2022","unstructured":"Meng G, Chen P, Du BL, Dong CL. Study on the distribution characteristics and inflfluencing factors of pathogenic Bacteria in patients with lung infection after Chemotherapy of Advanced Non-small Cell Lung Cancer. W Notes on Anti. 2022;43(2):112\u20134. https:\/\/doi.org\/10.13461\/j.cnki.wna.005446. (in Chinese).","journal-title":"W Notes on Anti"},{"issue":"7","key":"2681_CR20","first-page":"47","volume":"42","author":"HX Tuo","year":"2022","unstructured":"Tuo HX, Sun X. Distribution and drug resistance of pathogenic bacteria in patients with nosocomial pulmonary infection after lung cancer surgery. Cli Med. 2022;42(7):47\u20139. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=EBED202207016. &DbName=CJFQ2022 (in Chinese).","journal-title":"Cli Med"},{"issue":"5","key":"2681_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.13493\/j.issn.1672-7878.2022.05-008","volume":"19","author":"HY Xu","year":"2022","unstructured":"Xu HY, Lu KB, Qu Z, Wang QF, Dong XM. Analysis of distribution and drug resistance of pathogenic Bacteria in sputum specimens of 349 Elderly patients with pulmonary infection after lung CancerSurgery. Anti Infect Pharm. 2022;19(5):648\u201352. https:\/\/doi.org\/10.13493\/j.issn.1672-7878.2022.05-008. (in Chinese).","journal-title":"Anti Infect Pharm"},{"issue":"4","key":"2681_CR22","first-page":"356","volume":"37","author":"JY Wang","year":"2022","unstructured":"Wang JY, Wang SS, Zhu J, Huang XC, Wan YX, Liu Y. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy. Lab Med. 2022;37(4):356\u20139. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=SHYY202204010. &DbName=CJFQ2022 (in Chinese).","journal-title":"Lab Med"},{"issue":"49","key":"2681_CR23","first-page":"2364","volume":"17","author":"JX Yang","year":"2022","unstructured":"Yang JX, Yang SG, Jiang B. Study on pathogenic bacteria characteristics of lung cancer chemotherapy combined with nosocomial lung infection. Shanxi Med J. 2022;17(49):2364\u20136. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=SXYY202017053. &DbName=CJFQ2020 (in Chinese).","journal-title":"Shanxi Med J"},{"key":"2681_CR24","unstructured":"Zhu J, Zhao DM, Chen JG, Wu BP. Distribution and drug resistance of pathogenic bacteria in lung infection of patients with lung cancer after chemotherapy. Lab Med Cli 2017, 14 (21):3170\u20133172.https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=JYYL201721015&DbName=CJFQ2017. (in Chinese)."},{"issue":"9","key":"2681_CR25","first-page":"1611","volume":"20","author":"M Zhang","year":"2015","unstructured":"Zhang M, Liu WJ, Hao L, Zhao L, Zhu SY. Distribution and drug resistance of pathogens causing pulmonary infections in advanced lung cancer patients complicated with chronic obstructive pulmonary disease after chemotherapy. J Cli Pulmonary Sci. 2015;20(9):1611\u20134. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=LCFK201509019. &DbName=CJFQ2015 (in Chinese).","journal-title":"J Cli Pulmonary Sci"},{"issue":"22","key":"2681_CR26","first-page":"772","volume":"12","author":"QH Bao","year":"2019","unstructured":"Bao QH, Zhou H, Chen Q, Yang Q, Zhou JY. Characteristics and influencing factors of pathogenic Bacteria in Lung Cancer Chemotherapy combined with nosocomial pulmonary infection. Chin J Lung Cancer. 2019;12(22):772\u20138. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=FAIZ201912007. &DbName=CJFQ2019 (in Chinese).","journal-title":"Chin J Lung Cancer"},{"issue":"11","key":"2681_CR27","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.13493\/j.issn.1672-7878.2020.11-017","volume":"17","author":"YL Zhang","year":"2020","unstructured":"Zhang YL. Bacterial culture of sputum samples from 136 patients with nosocomial pulmonary infection after lung cancer chemotherapy and analysis of antimicrobial resistance. Anti Infect Pharm. 2020;17(11):1614\u20136. https:\/\/doi.org\/10.13493\/j.issn.1672-7878.2020.11-017. (in Chinese).","journal-title":"Anti Infect Pharm"},{"issue":"08","key":"2681_CR28","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.13493\/j.issn.1672-7878.2021.08-008","volume":"18","author":"ZW Zhu","year":"2021","unstructured":"Zhu ZW. Analysis of distribution and drug resistance of pathogenic Bacteria in specimens of 159 Lung Cancer patients with pulmonary infection after Chemotherapy. Anti Infect Pharm. 2021;18(08):1114\u20137. https:\/\/doi.org\/10.13493\/j.issn.1672-7878.2021.08-008. (in Chinese).","journal-title":"Anti Infect Pharm"},{"issue":"6","key":"2681_CR29","first-page":"142","volume":"44","author":"Z Wang","year":"2021","unstructured":"Wang Z. The status quo, pathogenic bacteria distribution and risk factors of postoperative pulmonary infection in patients with lung cancer. Heilongjiang Med Sci. 2021;44(6):142\u20133. https:\/\/kns.cnki.net\/kcms\/detail\/detail.aspx?FileName=KXJY202106061. &DbName=CJFQ2021 (in Chinese).","journal-title":"Heilongjiang Med Sci"},{"issue":"08","key":"2681_CR30","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.13493\/j.issn.1672-7878.2021.08-010","volume":"18","author":"Z Liu","year":"2021","unstructured":"Liu Z, Zhang GZ. Analysis of Pathogens\u2019 distribution and drug resistance of pulmonary infection caused by radio-chemo-therapy in 124 patients with Lung Cancer. Anti Infect Pharm. 2021;18(08):1122\u20136. https:\/\/doi.org\/10.13493\/j.issn.1672-7878.2021.08-010. (in Chinese).","journal-title":"Anti Infect Pharm"},{"issue":"1","key":"2681_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CCO.0000000000000703","volume":"33","author":"F Wu","year":"2021","unstructured":"Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect. Curr Opin Oncol. 2021;33(1):40\u20136.","journal-title":"Curr Opin Oncol"},{"issue":"18Suppl 2","key":"2681_CR32","doi-asserted-by":"publisher","first-page":"s41","DOI":"10.7861\/clinmedicine.18-2-s41","volume":"1","author":"GS Jones","year":"2018","unstructured":"Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond). 2018;1(18Suppl 2):s41\u20136.","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"2681_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190\u20139.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02681-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T06:03:50Z","timestamp":1700460230000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02681-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2681"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02681-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report there are no competing interests to declare","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"402"}}